HC Wainwright Has Pessimistic View of CGEM FY2025 Earnings

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – HC Wainwright dropped their FY2025 earnings estimates for Cullinan Therapeutics in a research note issued to investors on Wednesday, January 29th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($2.74) per share for the year, down from their prior estimate of ($2.55). HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2025 earnings at ($0.20) EPS and FY2026 earnings at ($3.15) EPS.

Separately, UBS Group assumed coverage on shares of Cullinan Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $30.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $32.50.

Cullinan Therapeutics Trading Up 1.4 %

Shares of NASDAQ:CGEM opened at $10.20 on Monday. Cullinan Therapeutics has a 12-month low of $9.50 and a 12-month high of $30.19. The stock’s 50-day moving average price is $11.60 and its two-hundred day moving average price is $15.03. The firm has a market cap of $593.95 million, a price-to-earnings ratio of -3.59 and a beta of -0.16.

Cullinan Therapeutics (NASDAQ:CGEM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.09.

Insider Activity

In other news, CEO Nadim Ahmed sold 8,400 shares of the stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $11.87, for a total transaction of $99,708.00. Following the sale, the chief executive officer now directly owns 263,150 shares in the company, valued at approximately $3,123,590.50. This represents a 3.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jennifer Michaelson sold 3,489 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $12.52, for a total value of $43,682.28. Following the transaction, the insider now owns 104,453 shares of the company’s stock, valued at $1,307,751.56. This represents a 3.23 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 20,582 shares of company stock worth $246,977. 6.07% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Cullinan Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CGEM. RTW Investments LP lifted its position in Cullinan Therapeutics by 62.1% in the 3rd quarter. RTW Investments LP now owns 1,705,960 shares of the company’s stock valued at $28,558,000 after purchasing an additional 653,330 shares during the last quarter. Braidwell LP increased its position in Cullinan Therapeutics by 567.6% in the 3rd quarter. Braidwell LP now owns 1,176,173 shares of the company’s stock valued at $19,689,000 after acquiring an additional 1,000,000 shares during the period. Harbor Capital Advisors Inc. raised its stake in Cullinan Therapeutics by 43.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 30,747 shares of the company’s stock valued at $374,000 after acquiring an additional 9,385 shares in the last quarter. Geode Capital Management LLC boosted its position in Cullinan Therapeutics by 23.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,208,421 shares of the company’s stock worth $20,233,000 after acquiring an additional 231,935 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Cullinan Therapeutics by 25.1% in the third quarter. JPMorgan Chase & Co. now owns 29,110 shares of the company’s stock worth $487,000 after purchasing an additional 5,842 shares in the last quarter. Institutional investors and hedge funds own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.